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Abstract
Iron deficiency remains the most prevalent micronutrient deficiency worldwide. Iron deficiency in TB 
patients, causes a poor outcome, reccurency, and treatment failure. Iron supplements on TB patients with 
iron deficiency will activate macrophage-derived monocytes (MDM) and interferon-gamma (IFN-γ), with a positive feedback mechanism pushing interleukin-12 (IL-12). This study is a single-blind randomized 
control trial comparing the effectivity of preoperative iron supplementation in IL-12 level between two different groups in Dr. Hasan Sadikin General Hospital Bandung, conducted from November 2018 until March 
2019. Respondents are those having Spondylitis TB, with sTfR > 21,7 pg/mL and IL-12 <41 pg/mL, intensive 
phase antituberculosis drugs category 1. The experimental group, comprised 17 respondents, was treated 
with 2RHZE and 357mg iron (III) hidroxy polymaltosa. The control group was treated with 2RHZE. The 
sTfR and IL-12 levels were performed before and after treatment. The increase of IL-12 in the experimental 
group was +364,53% higher than in the control group (p<0.05). The decrease of sTfR in the experimental 
group was -60,68% higher than in the control group (p<0.05). The result of the Pearson correlation test was 
a  coefficient correlation of - 0,73, this showed that a decrease in the sTfR level correlated with an increase in 
the Il-12 level.  Iron supplement in Spondylitis TB  with iron deficiency  in the experimental group increases 
the IL-12 level. Preoperative iron supplementation on spondylitis TB with iron deficiency, increases the 
immune system with higher levels of IL-12.
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Perbedaan Kadar IL-12 pada Terapi Pre-Operatif Spondilitis TB 
dengan Defisiensi Zat Besi yang diberikan Suplementasi Zat Besi
Abstrak
Defisiensi Fe merupakan defisiensi mikronutrien paling sering di seluruh dunia, jika terjadi pada penderita TB akan meningkatkan risiko prognosa buruk, rekurensi, MDR, dan gagal terapi. Suplementasi besi pada 
tuberkulosa dengan defisiensi besi akan meningkatkan sistem imun dengan mengaktivasi macrophage derived monocyt, dan interferon-gamma, dengan mekanisme umpan balik positif memacu interleukin-12. Single blind randomized control trial untuk membandingkan efektivitas Fe terhadap kenaikan IL-12 pada terapi preoperatif spondilitis TB di RSHS periode  Nopember 2018- Maret 2019. Metode sampling;consecutive 
sampling. Subjek sebanyak 34 orang; Penderita spondilitis TB,  sTfR >21,7 pg/ml dan IL-12< 41 pg/mL. fase 
intensif OAT kategori 1sesuai dengan standar WHO. Kelompok eksperimen, 17responden diterapi 2 RHZE 
+ tablet iron (III) hidroksi polimaltosa357 mg selama 2 bulan. Kelompok kontrol 17 responden diterapi 
2RHZE. Peningkatan IL-12 pada kelompok eksperimen sebesar +364,53% lebih besar dari kelompok 
kontrol (p<0,05) dan; Penurunan kadar sTfR pada kelompok eksperimen sebesar –60,68% (p<0,05) lebih besar dari kontrol. Uji korelasi sTfR dan IL-12 dengan Pearson ; korelasi -0,763, menunjukkan korelasi kuat antara penurunan sTfR dan kenaikan nilai IL-12. Suplementasi Fe pada terapi preoperatif spondilitis TB 
dengan defisiensi Fe meningkatkan respon imun yang ditandai dengan meningkatnya IL-12.
Kata kunci: Interleukin-12, spondilitis  TB, zat besi
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Introduction
Tuberkulosis (TB) is one of the significant 
public health threats, competing with human 
immunodeficiency virus (HIV) as the cause of death due to infectious disease. In 2017, 
87% of new TB cases occurred in the 30 
high TB burden countries.1 Indonesia was in 
3rd position after India and China, with an 
incidence rate of 395 per 100.000 citizans and mortality rate 27,3 per 100.000 per citizen.1 
Over 95% of cases and deaths are in developing countries, including Indonesia.1 Major achievements have been made in reducing 
the global burden of TB with the expansion of efforts to improve TB care and control, but TB remains an important global health concern.2 Tuberculosis caused by bacteria mycobacterium tuberculosis most often affect the lungs.1,3 TB affects adults in their most 
productive years; however, all age groups are at risk.1 Nearly 20% of patients with TB develop extrapulmonary manifestations.1 Skeletal TB 
accounts for 10–20% of all extrapulmonary 
TB, with spinal involvement in 50–60% of all skeletal TB cases. This has been a tough challenge to all community to control this infection.3,4 Spinal TB is the most common and 
worst form of TB lesion; spinal TB can cause bone destruction, kyphosis deformity, and paraplegia.4,5 Motor and sensory neurological 
impairment were found in 77.1% of spinal TB cases.4 Because of the high morbidity rate 
with this disease, the authors are interested in research on the prevention, medication, and rehabilitation to reduce the rate of the morbidity and death due to TB.5 
Iron deficiency in tuberculosis have been reported since 1986, one study conducted by 
Baynes et al., states that iron deficiency reduce 
celuller immunity, even without anemia. Iron 
deficiency in TB patient is caused by several mechanism, such as malabsorption, reduction iron uptake in duodenum caused a reduction 
in the body’s ability to utilize sufficient iron for effective erythropoiesis by hepcidin expression in TB patients, iron acquisition from macrophage led to iron recycle restricted.2,6,7 
MTB extract iron from the extracelluler matrix that causes iron level decreasing.4Chronic or 
severe iron deficiency led to iron deficiency Anemia (IDA). Many studies had documented a high prevalence of anemia in TB patients 
(30–94 %), and evidence suggests that anemia in TB increases the risk of death. Any effort to 
alleviate Iron deficiency will improve treatment outcome of TB patients.2 Iron is necessary for survival of all cells in culture. Iron is required for the activity of ribonucleotide reductase the enzyme responsible for synthesis of deoxyribonucleotides, and therefore is needed for DNA synthesis.8,9 
Iron deficiency is associated with reversible abnormalities of immune function. Both experimental, and some clinical studies have emphasized the importance of iron in the integrity of the immune system especially the innate immunity (decreased bactericidal effect and respiratory burst of neutrophils) and the cellular component system of cell-mediated immunity (CMI) (decreased lymphocyte proliferation and delayed hypersensitivity responses).2 
A study was conducted by Subagyo et al. of iron as suplementation in pulmonary 
tuberculosis patients with iron deficiency 
anemia towards healing response, immune response and resistency.10 The study results 
show that iron supplementation enhances healing response measured by the conversion of BTA sputum. The immune response 
measured by increasing level of IFN-γ, IL-12, hemoglobin, IMT, and MDR resistence measured by double alkali mutation.4 As stated in a study by Tatar et al., the immune system in extrapulmonary TB patient is much 
lower than pulmonary TB patient.11 There is no research on iron supplementation in extrapulmonay TB, especially spondylitis TB, as among the severe ones. 
Efforts to identify and address the conditions contributing to TB-associated 
anemia, including iron deficiency, could play an essential role in reducing morbidity and mortality in areas profoundly affected. Our 
research aimed to determine whether oral iron supplementation as a supplement can 
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increase the effectivity of anti-tuberculous drugs (ATDs) through evaluating the immune marker cytokine inteleukin-12 (IL-12) in 
spondylitis TB patient with iron deficiency.   This study used soluble transferrin receptor (sTfR) to asess the iron level. StfR is a transferrin protein derived from erythroid 
cells. StfR will increase in response to low supply of iron to the tissue; it is a sensitive 
response to early iron deficiency. The advantages of sTfr tests are unaffected by 
infection or inflammation process, age, gender nor pregnancy.
Methods This study used a single-blind randomized controlled trial design. All spinal TB patients 
at the Hasan Sadikin Hospital, who were 
medicated with ATD and met the inclusion 
and exclusion criteria, were randomLy 
divided into two groups. Group 1 was the 
intervention group, which was given 357 mg iron polymaltose (III) tablet, and Group 
2 was the control group. Both groups were 
followed for two months and their sTfR and 
IL-12 level  measured at recruitment and two months after ATD medication. Laboratory 
examinations were performed in the Dr. Hasan Sadikin General Hospital laboratory. The sTfR and IL-12 serum concentration examinations 
used a colorimetric reader using ELISA tests. 
The research subjects were all spinal TB outpatients or inpatients at Dr. Hasan Sadikin General Hospital Bandung. The inclusion 
criteria were age: 18–55 years; sTfR >21,7 pg/
mL.; IL-12  < 41 pg/mL. Exclusion criteria were a history of TB, diabetes mellitus, hypertension, autoimmune disease, or thyroid disease; a long-term steroid medication; lung or kidney function disorder; pregnant or breastfeeding 
woman; Regulary took medication Allopurinol, Antacid, H2 receptor block (ranitidine), proton pump inhibitor. Repetitive transfusion, iron disorder, and  allergic to iron. Research 
subjects were dropped from the study if they 
received surgery within the research period.This study used a consecutive sampling 
method with 17 people in each group. The intervention group received iron polymaltose 
(III) tablet+ ATD. The control group only 
received ATD. For the relationship between 
sTfR and changes in IL-12 concentration, we used the independent t-test. To analyze the 
correlation between sTfR and IL-12 we used the Spearman and the Pearson correlation tests.This study has been approved by the 
Ethical Committee of Dr. Hasan Sadikin General 
Hospital Bandung, with the ethical approval 
number LB.04.01/A05/EC/315/XI/2018.
ResultsCharacteristics of each group (sex, age, BMI, location of lesion, severity of lesion by Frankle 
classification and Haemoglobin) showed that 
the average age in the intervention group was 
31.8 years [standard deviation (SD)±11.65] 
and in the control group was 40,29 years 
Table 1 Table characteristics
Characteristics
ATD + 357 mg 
iron polymaltose (III)
(n=17)
ATD
(n=17)Sex Male  Female 98 89Age (years), average (SD) 31,88, (11,65) 40,29, (12,89)Body mass index (BMI) (kg/m2 ), average (SD) 20,0, (2,64) 19,4, (2,38)Spine level (frequency) Thoracal Lumbal 98 107Haemoglobin pre-treatmet, mean 10,09. (2,59) 10,55. (1,68)
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(SD ±12,89). The average BMI was 20.0 kg/m2 (SD±2,64) in intervension group and 19.4 (SD±2.38) in the control group. The differences 
in characteristics between the groups were 
not statistically significant (Table 1).Furthermore, the different level of sTfR and 
IL-12 before treatment was not signifficant. The sTfR concentration in the intervention group 
before supplementation was 56,12 pg/mL, 
and after supplementation, it was 35.61 pg/
mL. Differences were analyzed with the paired 
t-test and found to be statistically significant 
(p<0.001). It was significant that the decrease 
of the sTfR level was after treatment compared 
with before treatment (Table 2).
Similarly, there was a statistically 
significant increase in IL-12 concentrations 
after supplementation with 357 mg iron 
polymaltose (III) for two months (p<0.001 and 
p<0.03, respectively) (Table 2).
Correlation between stFr and IL-12 concentration before and after vitamin Fe supplementation used the Pearson test. There 
was a significant correlation between the decreasing level of sTfR and increasing level of 
IL-12, with a coefficient -0,763.
DiscussionAfter randomization, the potentially 
confounding variables were found distributed 
evenly between the intervention group and the control group (Table 1). In this study, Gibbus 
deformity was typically located in the thoracic 
vertebrae. It is caused by the Adamkiewicz artery, a segmental blood vessel located in the thoracolumbar vertebral region. This artery supplies the body of the vertebrae and might carry MTB bacteria to the vertebrae.5 Spondylitis TB is a serious problem for public health12 that often occurs in high burden TB incidence such as Indonesia.  According to The British Medical Research Council Working Party on Spinal Tuberculosis,12,13 antituberculosis drug (ATD) is the primary 
treatment for spondylitis TB without complications. ATD has improved the results of conservative and radical restorative operative treatments.5,13 TB is a catabolic disease that 
consumes much energy, with  symptoms 
such  as decreasing body weight, anemia, malnutrition, and hypoproteinemia, making 
it difficult to provide a suitable  environment for healing. Furthermore, Cao et al report nutritional status as one of the responsible 
factors for worse prognosis.17 Besides, Wang 
et al report a low level of haemoglobin as predisposition factor for reccurence and postoperative sinus tract complications in spondylitis TB treatment; Wang reccomended preoperative fresh erytrocyte suspension and albumin transfusion.15 Moreover, Froissat et al. report that red blood cell transfusion 
will not influence the sTfR level, which means fungsional iron level is unaffected 
by transfusion. Iron deficiency cannot be 
Table 2 Correlation IL-12 and sTfR concentration in the intervention group before and after 
  Fe supplementation
ATD + 357 mg iron 
polymaltose (III) ATD p valueIL-12 (pg/mL) avarage)Before (min; max) 14,16 (3,98 ; 30,45 ) 13, 99 (2,48; 28,04) #0,943After (min; max) 63,23 (38, 22; 105, 36 ) 30, 24 ( 16,42 ; 53, 13) #0,000 Difference (min; max) 49, 07 (34, 24 ; 74, 91) 16, 25 (13, 94; 25, 09) #0,000sTfR (pg/mL) Avarage (min; max) Before (min; max) 56, 12 (50, 13 ; 79,19) 57,87 (50, 87 ; 76, 31) #0, 982After (min; max) 20, 51 (26, 95; 12, 41) 36,26 (40, 15; 26, 62) #0.000 Difference (min; max) 35, 61 (23,18; 66,78) 21,61 (10,72 ; 49,62) #0,000
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corrected by blood transfusion.16  A study by Subagyo et al.10 reports that iron as supplementation in pulmonary 
tuberculosis patients with iron deficiency 
anemia enhances Immune response, which is 
measured by increasing level IFN-γ and  IL-12.We studied the effect of preoperative iron 
supplementation in iron deficiency spondylitis 
TB patients with IL-12 parameter. Haemoglobin level for both groups had 
an almost similiar average level, which 
was 10,09gr/dL on the intervention group, 
and 10.55 gr/dL on the control group. It observed that the Hb level did not decrease 
below 10gr/dl. However, both groups were 
categorized as iron deficiency. The mean for 
sTfR concentration in the control group was 
57,92 pg/mL, while in the intervention group 
was 57,87 pg/mL. Both groups showed iron 
deficiency. Whereas WHO categorizes iron 
deficiency as sTfR >21,7 pg/mL.
Iron deficiency without anemia can 
occur when in early phase or not severe enough to decrease heamoglobin level.17 The 
increasing Hb level in our study was 3 times higher  than in the previous study. Increasing Hb level is caused by iron supplementation promoting the amount of erytrocyte, iron deposition, functional iron level, and enhance haematopoiesis. Increasing the Hb level in 
this study was not significant, it may be due to the short duration of this study, less than erytrocyte production time 120 days. A study by Minchella et al. concludes that Hb increases 
in tuberculosis patients after 2 months with ATD drugs.18  
Elevated IL-12 post-treatment in this 
study was 0.5 times higher than in the previous study on pulmonary TB. IL-12 in the 
control group was increasing also. In adition to the antimicrobial effect, ATD also has an imunostimulator effect.19 De Oliver et al. report post-ATD treatment in pulmonary TB receptor and expression of both limphocytes and monocytes, therefore IL-12 in the control group  also increased.20 The correlation test 
used the Pearson method between sTfR 
and IL-12 with coefficient correlation -0,73, 
which means a strong correlation between 
decreasing sTfR level to increasing il-12. Iron supplementation increasing IL-12 is caused by activated macrophage derived monocyte and activate latent phase into active phase of IL-12.10 This is probably due to the shorter duration of this study than  increasing the iron enterocyte deposition. Decrease level of StfR post-treatment 
35,61 pg/mL, is lower in a previous study 
on pulmonary TB. This was possibly caused by the shorter  duration of this study. Iron suplementation leads to a reduced receptor in the plasma membrane and increasing iron enterocyte deposition; therefore stfR is decreased.10 ATD without iron suplementation 
will increase iron level due to reduce 
inflammation leads to decreasing siderophores and ferritin; therefore iron acquisition by 
MTb was decreased and iron absorption was increased.6 The averange iron level post-
treatment in the control group was 36,26 pg/mL and still above  21,7 pg/mL; therefore iron 
deficiency in the control group was not been corrected. Subagyo et al. report baseline for multiple 
drug resistence for pulmonary TB is sTfR> 
60,26 pg/mL, IL-12<15,56 pg/mL, Hb 9,5 
gr%.10 Although there was not  a study baseline for spondylitis TB, this should be considered given both spondylitis TB and pulmonary TB are caused by similar microorganisme and pathology. In our control group post-treatment 
study  were four subjects that had IL-12 level 
below baseline, three subjects with sTfR level 
above the baseline, and four subjects with Hb 
below baseline. In the control group study 
there were seven subjects (41,18%) that got a 
risk of MDR, and one subject with a multiple risk factor. Whereas in the intervention group, 
only three subjects (17,65%)  got a risk factor of MDR, none of them reached the base line for sTfR and IL-12 level. From our study, it appeared that iron supplementation group 
had a lower risk of MDR compared to the control group. 
In this study, those factors were among the uncontrollable factors. So, the samples that are not homogenous become potentially 
making the two groups less homogeneous, 
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which is one of the  limitations of this study. Other limitations of this study are the inability to control the location of participant activities 
and their food consumption which might affect the iron concentration, and also the lack of patients’ adherence proof to the regime of consuming iron every day.
Conclusion
Supplementation of Iron Polymaltose 357 mg 
increases the efficacy of ATD in spondylitis 
TB with iron deficiency management. Iron 
Polymaltose 357 mg is an appropriate 
supplement in spondylitis TB with iron 
deficiency treatment regimen.
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